Profile data is unavailable for this security.
About the company
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceutical products segment. Its geographical segments include within India and outside India. The Company has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies Paracetamol, Metformin, Guaifenesin, and Methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the United States. The Company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. Its subsidiaries include Granules USA Inc and Granules Europe Limited. It also owns Senn Chemicals AG, a contract development and manufacturing organization (CDMO) specializing in peptide development and manufacturing.
- Revenue in INR (TTM)50.92bn
- Net income in INR5.45bn
- Incorporated1991
- Employees4.07k
- LocationGranules India Ltd2nd Floor3rd Block, My Home Hub MadhapurHYDERABAD 500081IndiaIND
- Phone+91 4 069043500
- Fax+91 4 023115145
- Websitehttps://granulesindia.com/
More ▼
Mergers & acquisitions
| Acquired company | GRANULES:NSI since announced | Transaction value |
|---|---|---|
| Optus 1039. GmbH | 3.90% | 28.00k |
| Senn Chemicals AG | 7.41% | -- |
Data delayed at least 15 minutes, as of Feb 16 2026 10:27 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marksans Pharma Ltd | 28.03bn | 3.60bn | 82.36bn | 1.35k | 22.84 | -- | 17.95 | 2.94 | 7.96 | 7.96 | 61.92 | -- | -- | -- | -- | 20,780,450.00 | -- | 14.15 | -- | 17.41 | 56.77 | 51.56 | 12.90 | 14.58 | -- | 20.42 | -- | 7.77 | 20.46 | 18.25 | 21.32 | 26.60 | 23.73 | 51.57 |
| Procter & Gamble Health Ltd | 13.49bn | 2.93bn | 82.81bn | 1.33k | 28.24 | -- | 26.18 | 6.14 | 176.64 | 176.64 | 811.45 | -- | -- | -- | -- | 10,169,760.00 | -- | -- | -- | -- | 72.49 | -- | 21.76 | -- | -- | 806.81 | -- | -- | -- | -- | -- | -- | -- | -- |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 86.81bn | 3.76k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.29 | -- | 40.74 | -- | 92.07 | -- | 16.78 | -- | -- | -- | -- | 44.59 | 37.80 | 31.10 | 73.77 | 47.62 | -- |
| Sanofi India Ltd | 19.33bn | 3.56bn | 92.97bn | 991.00 | 26.09 | -- | 23.61 | 4.81 | 154.71 | 154.71 | 839.09 | -- | -- | -- | -- | 19,500,500.00 | -- | 22.31 | -- | 31.44 | 51.42 | 54.10 | 18.44 | 21.53 | -- | 321.27 | -- | 132.73 | 0.8567 | -8.10 | -13.96 | -5.41 | -13.65 | 1.99 |
| Viyash Scientific Ltd | 21.26bn | 768.08m | 94.36bn | 1.24k | 91.13 | -- | 46.88 | 4.44 | 2.37 | 2.37 | 70.40 | -- | -- | -- | -- | 17,086,170.00 | -- | 0.4014 | -- | 0.6553 | 51.15 | 42.16 | 4.52 | 0.4199 | -- | 3.92 | -- | 995.91 | 13.26 | 5.64 | 160.99 | -20.73 | -0.126 | -- |
| Corona Remedies Ltd | 13.44bn | 1.71bn | 97.43bn | 4.57k | 56.87 | -- | 46.63 | 7.25 | 28.01 | 28.01 | 219.70 | -- | -- | -- | -- | 2,980,876.00 | -- | -- | -- | -- | 81.28 | -- | 12.75 | -- | -- | 55.10 | -- | -- | 17.93 | -- | 65.11 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | 8.16bn | 2.18bn | 98.81bn | 583.00 | 45.35 | -- | 43.49 | 12.10 | 94.62 | 94.62 | 354.49 | -- | -- | -- | -- | 14,003,430.00 | -- | -- | -- | -- | 75.05 | -- | 26.69 | -- | -- | 143.16 | -- | -- | 30.45 | -- | 9.76 | -- | -- | -- |
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 112.89bn | 2.20k | 20.80 | -- | 18.36 | 4.49 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
| Cohance Lifesciences Ltd | 20.51bn | 2.02bn | 120.74bn | 1.21k | 54.40 | -- | 35.16 | 5.89 | 5.80 | 5.80 | 58.32 | -- | -- | -- | -- | 16,926,160.00 | -- | 18.62 | -- | 20.90 | 71.62 | 60.82 | 8.80 | 30.28 | -- | 7.07 | -- | 15.59 | 13.91 | 7.51 | -10.79 | -3.31 | 9.39 | -- |
| Concord Biotech Ltd | 11.59bn | 3.12bn | 123.91bn | 1.57k | 39.86 | -- | 32.55 | 10.69 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 131.59bn | 990.00 | 21.51 | -- | 18.98 | 6.30 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Granules India Ltd | 50.92bn | 5.45bn | 136.46bn | 4.07k | 25.02 | -- | 16.57 | 2.68 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 144.59bn | 978.00 | 33.53 | -- | 17.04 | 1.83 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 147.56bn | 4.20k | 9.48 | -- | 8.20 | 3.24 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 151.33bn | 16.57k | 24.01 | -- | 16.36 | 2.08 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 167.51bn | 1.80k | 93.51 | -- | 63.77 | 10.63 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
Data as of Feb 16 2026. Currency figures normalised to Granules India Ltd's reporting currency: Indian Rupee INR
16.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2025 | 12.94m | 5.33% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 5.69m | 2.35% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Jan 2026 | 4.94m | 2.04% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 4.40m | 1.81% |
| Tata Asset Management Pvt Ltd.as of 31 Jan 2026 | 2.68m | 1.10% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Dec 2025 | 2.64m | 1.09% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 2.61m | 1.07% |
| Edelweiss Asset Management Ltd.as of 31 Jan 2026 | 2.36m | 0.97% |
| Old Bridge Asset Management Pvt Ltd.as of 31 Dec 2025 | 1.58m | 0.65% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 1.07m | 0.44% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
